Current treatment for liver metastases from colorectal cancer

被引:109
作者
Liu, LX [1 ]
Zhang, WH [1 ]
Jiang, HC [1 ]
机构
[1] Harbin Med Univ, Dept Surg, Clin Coll 1, Harbin 150001, Heilongjiang, Peoples R China
关键词
D O I
10.3748/wjg.v9.i2.193
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The liver is the commonest site of distant metastasis of colorectal cancer and nearly half of the patients with colorectal cancer ultimately develop liver involved during the course of their diseases. Surgery is the only therapy that offers the possibility of cure for patients with hepatic metastatic diseases. Five-year survival rates after resection of all detectable liver metastases can be up to 40 %. Unfortunately, only 25 % of patients with colorectal liver metastases are candidates for liver resection, while the others are not amenable to surgical resection. Regional therapies such as radiofrequency ablation and cryotherapy may be offered to patients with isolated unresectable metastases but no extrahepatic diseases. Hepatic artery catheter chemotherapy and chemoembolization and portal vein embolization are often used for the patients with extensive liver metastases but without extrahepatic diseases, which are not suitable for regional ablation. For the patients with metastatic colorectal cancer beyond the liver, systemic chemotherapy is a more appropriate choice. Immunotherapy is also a good option when other therapies are used in combination to enhance the efficacy. Selective internal radiation therapy is a new radiation method which can be used in patients given other routine therapies without effects.
引用
收藏
页码:193 / 200
页数:8
相关论文
共 127 条
[1]   Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy [J].
Abramson, RG ;
Rosen, MP ;
Perry, LJ ;
Brophy, DP ;
Raeburn, SL ;
Stuart, KE .
RADIOLOGY, 2000, 216 (02) :485-491
[2]   QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES [J].
ALLENMERSH, TG ;
EARLAM, S ;
FORDY, C ;
ABRAMS, K ;
HOUGHTON, J .
LANCET, 1994, 344 (8932) :1255-1260
[3]  
ANDRIGHETTI L, 2002, HEPATO-GASTROENTEROL, V49, P513
[4]   Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver [J].
Azoulay, D ;
Castaing, D ;
Krissat, J ;
Smail, A ;
Hargreaves, GM ;
Lemoine, A ;
Emile, JF ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (05) :665-672
[5]   Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization [J].
Azoulay, D ;
Castaing, D ;
Smail, A ;
Adam, R ;
Cailliez, V ;
Laurent, A ;
Lemoine, A ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 231 (04) :480-486
[6]   Treatment of liver metastases from colorectal cancer: what is the best approach today? [J].
Biasco, G ;
Gallerani, E .
DIGESTIVE AND LIVER DISEASE, 2001, 33 (05) :438-444
[7]   Radiofrequency ablation of unresectable hepatic malignancies: Lessons learned [J].
Bilchik, AJ ;
Wood, TF ;
Allegra, DP .
ONCOLOGIST, 2001, 6 (01) :24-33
[8]   Transcatheter embolization for the treatment of misperfusion after hepatic artery chemoinfusion pump implantation [J].
Bloom, AI ;
Gordon, RL ;
Ahl, KH ;
Kerlan, RK ;
LaBerge, JM ;
Wilson, MW ;
Venook, AP ;
Warren, R .
ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (04) :350-358
[9]   Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma [J].
Bolton, JS ;
Fuhrman, GM .
ANNALS OF SURGERY, 2000, 231 (05) :743-750
[10]  
Boykin KN, 1999, AM SURGEON, V65, P1183